OptimizeRx Expands NPI Reach by 37% with Four New Partner Agreements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy OPRX?
Source: Newsfilter
- Network Expansion: OptimizeRx has signed an exclusive multi-year agreement with a high-demand e-prescribing platform, significantly expanding its point-of-care network and enhancing its competitive position in the market.
- NPI Reach Increase: The addition of two new channel partners boosts OptimizeRx's National Provider Identifier (NPI) reach by 37%, directly enhancing clients' access to healthcare providers during treatment planning.
- Long-term Renewals: The company has renewed multi-year agreements with two top-performing electronic health record (EHR) and eRx platforms, one of which establishes an exclusive partnership, securing access to premium inventory.
- Strategic Growth Positioning: CEO Steve Silvestro stated that by deepening relationships with high-value partners, OptimizeRx is positioning itself for sustained profitable growth, enhancing clients' brand awareness and conversion rates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPRX
Wall Street analysts forecast OPRX stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.580
Low
17.00
Averages
24.33
High
32.00
Current: 7.580
Low
17.00
Averages
24.33
High
32.00
About OPRX
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Whetstone Capital Fully Exits GitLab Holdings
- Holding Change: Whetstone Capital Advisors reported in a February 13, 2026 SEC filing that it sold its entire 192,532-share stake in GitLab, with an estimated transaction value of approximately $8.68 million, indicating a significant loss of confidence in the company.
- Market Performance: As of February 12, 2026, GitLab shares were priced at $29.58, reflecting a 57.6% decline over the past year and trailing the S&P 500 by 70.5 percentage points, highlighting the challenges the company faces in a competitive landscape.
- Company Overview: GitLab is a leading provider of DevOps lifecycle software, focusing on streamlining and securing software development processes through a unified platform; however, it faces competitive pressure from AI-assisted coding and must adapt to market demands.
- Investor Focus: As companies reconsider vendor consolidation or adding AI layers, GitLab must standardize its platform and increase enterprise adoption to achieve sustained growth, particularly as demand weakens in some public sector segments and among smaller customers.
See More
Whetstone Capital Fully Exits GitLab Position
- Share Sale Details: Whetstone Capital Advisors sold all 192,532 shares of GitLab, with an estimated transaction value of $8.68 million, reflecting a significant decline in confidence towards GitLab, resulting in a quarter-end position value drop to zero.
- Asset Management Impact: This transaction represented 2.7% of Whetstone's 13F reportable AUM, down from 2.4% previously, indicating a notable shift in the fund's investment strategy regarding GitLab.
- Market Performance Analysis: As of February 12, 2026, GitLab shares were priced at $29.58, down 57.6% over the past year and lagging the S&P 500 by 70.5 percentage points, suggesting low market expectations for its future growth.
- Strategic Development Challenges: As a leading provider of DevOps lifecycle software, GitLab faces pressures from AI-assisted coding and the need for enterprises to simplify fragmented toolchains, necessitating a conversion of AI integration and customer engagement into sustained enterprise growth while maintaining operational leverage.
See More
Whetstone Capital Fully Exits monday.com Position
- Share Sale Details: Whetstone Capital disclosed on February 13, 2026, that it sold all 79,172 shares of monday.com during Q4 2025, valued at approximately $15.33 million, resulting in a decrease in quarter-end position value due to both share disposition and price movement.
- Market Performance Analysis: As of February 12, 2026, monday.com shares were priced at $73.63, reflecting a 76.8% decline over the past year, significantly underperforming the S&P 500 Index by 89.7 percentage points, indicating its weak market position.
- Investor Impact: This transaction represents the largest of the 12 positions Whetstone closed in Q4 2025; while the fund did not elaborate on its decision, it suggests a cautious stance towards SaaS stocks amid AI advancements potentially replacing their functions.
- Industry Outlook: Despite the sale of monday.com, Whetstone continues to hold 54 tech-related stocks and opened a position in fintech stock Block in Q4, indicating ongoing interest in technology investments, even as the market landscape evolves.
See More
Whetstone Capital Fully Exits monday.com Position
- Position Change: On February 13, 2026, Whetstone Capital Advisors disclosed in an SEC filing that it sold all 79,172 shares of monday.com during Q4 2025, with an estimated trade value of $15.33 million, resulting in a $15.33 million decrease in quarter-end position value due to both share sale and price movement.
- AUM Impact: This transaction represented a 4.8% change in Whetstone's 13F reportable assets under management (AUM), with the position previously accounting for 4.2% of the fund's AUM in the prior quarter, highlighting the significance of monday.com in its portfolio.
- Market Trend: The sale reflects Whetstone's cautious stance towards SaaS stocks, particularly as AI technology increasingly replaces their functions and the market positioning remains unclear, indicating a prudent approach to future market changes.
- Investor Guidance: While Whetstone exited monday.com, it still holds 54 stocks tied to the tech sector and opened a position in fintech stock Block in Q4, demonstrating ongoing interest in the technology space.
See More
OptimizeRx Partners with Experian to Enhance DTC Marketing Effectiveness
- Data Integration Innovation: The collaboration between OptimizeRx and Experian integrates Micro-Neighborhood® audiences with Experian's identity graph, enabling life science brands to reach consumers more accurately, which is expected to significantly enhance the effectiveness of marketing campaigns.
- Audience Coverage Improvement: The new system reduces audience loss during the media onboarding process, which is projected to increase overall media reach, thereby enhancing brand influence in a competitive market.
- Precision Measurement Capability: By optimizing audience mapping, life science brands can measure exposed audiences more accurately, providing a more transparent view of engagement that will help brands optimize their marketing strategies and improve ROI.
- Privacy Safety Assurance: OptimizeRx's Micro-Neighborhood® audiences utilize privacy-compliant data, ensuring that consumer privacy needs are met while enhancing brands' marketing capabilities, further solidifying their leadership position in the healthcare technology sector.
See More
OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%
- Partnership Expansion: OptimizeRx has signed an exclusive multi-year agreement with a high-demand e-prescribing platform, significantly enhancing its in-workflow point-of-care network and fortifying its competitive position in the market.
- NPI Reach Increase: The addition of new partners boosts OptimizeRx's National Provider Identifier (NPI) reach by 37%, enabling clients to engage healthcare providers more effectively within clinical workflows.
- Renewal Strengthening: The company has renewed multi-year agreements with two top-performing electronic health record (EHR) and eRx platforms, one of which establishes an exclusive partnership, ensuring visibility into future channel revenue.
- Strategic Positioning: CEO Steve Silvestro stated that by deepening relationships with high-value partners, OptimizeRx is laying the groundwork for sustained profitable growth, addressing life sciences manufacturers' demand for in-workflow engagement.
See More
Whetstone Capital Fully Exits GitLab Holdings
- Holding Change: Whetstone Capital Advisors reported in a February 13, 2026 SEC filing that it sold its entire 192,532-share stake in GitLab, with an estimated transaction value of approximately $8.68 million, indicating a significant loss of confidence in the company.
- Market Performance: As of February 12, 2026, GitLab shares were priced at $29.58, reflecting a 57.6% decline over the past year and trailing the S&P 500 by 70.5 percentage points, highlighting the challenges the company faces in a competitive landscape.
- Company Overview: GitLab is a leading provider of DevOps lifecycle software, focusing on streamlining and securing software development processes through a unified platform; however, it faces competitive pressure from AI-assisted coding and must adapt to market demands.
- Investor Focus: As companies reconsider vendor consolidation or adding AI layers, GitLab must standardize its platform and increase enterprise adoption to achieve sustained growth, particularly as demand weakens in some public sector segments and among smaller customers.
See More
Whetstone Capital Fully Exits GitLab Position
- Share Sale Details: Whetstone Capital Advisors sold all 192,532 shares of GitLab, with an estimated transaction value of $8.68 million, reflecting a significant decline in confidence towards GitLab, resulting in a quarter-end position value drop to zero.
- Asset Management Impact: This transaction represented 2.7% of Whetstone's 13F reportable AUM, down from 2.4% previously, indicating a notable shift in the fund's investment strategy regarding GitLab.
- Market Performance Analysis: As of February 12, 2026, GitLab shares were priced at $29.58, down 57.6% over the past year and lagging the S&P 500 by 70.5 percentage points, suggesting low market expectations for its future growth.
- Strategic Development Challenges: As a leading provider of DevOps lifecycle software, GitLab faces pressures from AI-assisted coding and the need for enterprises to simplify fragmented toolchains, necessitating a conversion of AI integration and customer engagement into sustained enterprise growth while maintaining operational leverage.
See More
Whetstone Capital Fully Exits monday.com Position
- Share Sale Details: Whetstone Capital disclosed on February 13, 2026, that it sold all 79,172 shares of monday.com during Q4 2025, valued at approximately $15.33 million, resulting in a decrease in quarter-end position value due to both share disposition and price movement.
- Market Performance Analysis: As of February 12, 2026, monday.com shares were priced at $73.63, reflecting a 76.8% decline over the past year, significantly underperforming the S&P 500 Index by 89.7 percentage points, indicating its weak market position.
- Investor Impact: This transaction represents the largest of the 12 positions Whetstone closed in Q4 2025; while the fund did not elaborate on its decision, it suggests a cautious stance towards SaaS stocks amid AI advancements potentially replacing their functions.
- Industry Outlook: Despite the sale of monday.com, Whetstone continues to hold 54 tech-related stocks and opened a position in fintech stock Block in Q4, indicating ongoing interest in technology investments, even as the market landscape evolves.
See More
Whetstone Capital Fully Exits monday.com Position
- Position Change: On February 13, 2026, Whetstone Capital Advisors disclosed in an SEC filing that it sold all 79,172 shares of monday.com during Q4 2025, with an estimated trade value of $15.33 million, resulting in a $15.33 million decrease in quarter-end position value due to both share sale and price movement.
- AUM Impact: This transaction represented a 4.8% change in Whetstone's 13F reportable assets under management (AUM), with the position previously accounting for 4.2% of the fund's AUM in the prior quarter, highlighting the significance of monday.com in its portfolio.
- Market Trend: The sale reflects Whetstone's cautious stance towards SaaS stocks, particularly as AI technology increasingly replaces their functions and the market positioning remains unclear, indicating a prudent approach to future market changes.
- Investor Guidance: While Whetstone exited monday.com, it still holds 54 stocks tied to the tech sector and opened a position in fintech stock Block in Q4, demonstrating ongoing interest in the technology space.
See More
OptimizeRx Partners with Experian to Enhance DTC Marketing Effectiveness
- Data Integration Innovation: The collaboration between OptimizeRx and Experian integrates Micro-Neighborhood® audiences with Experian's identity graph, enabling life science brands to reach consumers more accurately, which is expected to significantly enhance the effectiveness of marketing campaigns.
- Audience Coverage Improvement: The new system reduces audience loss during the media onboarding process, which is projected to increase overall media reach, thereby enhancing brand influence in a competitive market.
- Precision Measurement Capability: By optimizing audience mapping, life science brands can measure exposed audiences more accurately, providing a more transparent view of engagement that will help brands optimize their marketing strategies and improve ROI.
- Privacy Safety Assurance: OptimizeRx's Micro-Neighborhood® audiences utilize privacy-compliant data, ensuring that consumer privacy needs are met while enhancing brands' marketing capabilities, further solidifying their leadership position in the healthcare technology sector.
See More
OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%
- Partnership Expansion: OptimizeRx has signed an exclusive multi-year agreement with a high-demand e-prescribing platform, significantly enhancing its in-workflow point-of-care network and fortifying its competitive position in the market.
- NPI Reach Increase: The addition of new partners boosts OptimizeRx's National Provider Identifier (NPI) reach by 37%, enabling clients to engage healthcare providers more effectively within clinical workflows.
- Renewal Strengthening: The company has renewed multi-year agreements with two top-performing electronic health record (EHR) and eRx platforms, one of which establishes an exclusive partnership, ensuring visibility into future channel revenue.
- Strategic Positioning: CEO Steve Silvestro stated that by deepening relationships with high-value partners, OptimizeRx is laying the groundwork for sustained profitable growth, addressing life sciences manufacturers' demand for in-workflow engagement.
See More
